Your browser doesn't support javascript.
loading
Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib.
Richardson, Paul G; Nagler, Arnon; Ben-Yehuda, Dina; Badros, Ashraf; Hari, Parameswaran N; Hajek, Roman; Spicka, Ivan; Kaya, Hakan; LeBlanc, Richard; Yoon, Sung-Soo; Kim, Kihyun; Martinez-Lopez, Joaquin; Mittelman, Moshe; Shpilberg, Ofer; Blake, Paul; Hideshima, Teru; Colson, Kathleen; Laubach, Jacob P; Ghobrial, Irene M; Leiba, Merav; Gatt, Moshe E; Sportelli, Peter; Chen, Michael; Anderson, Kenneth C.
Afiliação
  • Richardson PG; Jerome Lipper Center for Multiple Myeloma Research Dana-Farber Cancer Institute Boston Massachusetts USA.
  • Nagler A; Chaim Sheba Medical Center Tel Hashomer Israel.
  • Ben-Yehuda D; Hadassah University Hospital Jerusalem Israel.
  • Badros A; Greenebaum Comprehensive Cancer Center University of Maryland Baltimore Maryland USA.
  • Hari PN; Department of Hematology/Oncology Medical College of Wisconsin Milwaukee Wisconsin USA.
  • Hajek R; Department of Hematooncology University Hospital, Ostrava, and Faculty of Medicine University of Ostrava Ostrava Czech Republic.
  • Spicka I; First Department of Medicine, Department of Hematology First Faculty of Medicine Charles University and General Hospital in Prague Prague Czech Republic.
  • Kaya H; Cancer Care Northwest Spokane Washington USA.
  • LeBlanc R; CIUSSS de l'est de l'île de Montréal University of Montreal Montreal Canada.
  • Yoon SS; Department of Internal Medicine Seoul National University College of Medicine Seoul South Korea.
  • Kim K; Sungkyunkwan University School of Medicine Samsung Medical Center Seoul South Korea.
  • Martinez-Lopez J; Hospital Universitario 12 de Octubre CNIO Complutense University Madrid Spain.
  • Mittelman M; Tel Aviv Sourasky Medical Center Tel Aviv Israel.
  • Shpilberg O; Institute of Hematology Assuta Medical Centers Tel Aviv and Ariel University Ariel Israel.
  • Blake P; Aeterna Zentaris Frankfurt Germany.
  • Hideshima T; Jerome Lipper Center for Multiple Myeloma Research Dana-Farber Cancer Institute Boston Massachusetts USA.
  • Colson K; Jerome Lipper Center for Multiple Myeloma Research Dana-Farber Cancer Institute Boston Massachusetts USA.
  • Laubach JP; Jerome Lipper Center for Multiple Myeloma Research Dana-Farber Cancer Institute Boston Massachusetts USA.
  • Ghobrial IM; Jerome Lipper Center for Multiple Myeloma Research Dana-Farber Cancer Institute Boston Massachusetts USA.
  • Leiba M; Assuta Ashdod University Hospital Faculty of Health Sciences Ben-Gurion University of the Negev Beer-Sheba Israel.
  • Gatt ME; Hadassah University Hospital Jerusalem Israel.
  • Sportelli P; Keryx Biopharmaceuticals Inc. New York New York USA.
  • Chen M; TCM Groups Inc. Berkeley Heights New Jersey USA.
  • Anderson KC; Jerome Lipper Center for Multiple Myeloma Research Dana-Farber Cancer Institute Boston Massachusetts USA.
EJHaem ; 1(1): 94-102, 2020 Jul.
Article em En | MEDLINE | ID: mdl-35847734
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: EJHaem Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: EJHaem Ano de publicação: 2020 Tipo de documento: Article